Evidence map›Paper›PMID 35055060›Full record

ArticleInternational journal of molecular sciences2022

CD44, γ-H2AX, and p-ATM Expressions in Short-Term Ex Vivo Culture of Tumour Slices Predict the Treatment Response in Patients with Oral Squamous Cell Carcinoma.

Pierre Philouze, Arnaud Gauthier, Alexandra Lauret, Céline Malesys, Giovanna Muggiolu, Sylvie Sauvaigo, Antoine Galmiche, Philippe Ceruse, Gersende Alphonse, Anne-Sophie Wozny and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Biological biomarkers of oral cancer.Periodontology 2000 · 2024
    Review
  3. Article
  4. F1000Research · 2023
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Pierre PhilouzeLaboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France.
Arnaud GauthierLaboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France.
Alexandra LauretLaboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France.
Céline MalesysLaboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France.
Giovanna MuggioluLXRepair, 38700 La Tronche, France.
Sylvie SauvaigoLXRepair, 38700 La Tronche, France.
Antoine GalmicheUMR7516 "CHIMERE", University of Picardie Jules Verne-Department of Biochemistry of the Amiens Hospital, 80054 Amiens, France.ORCID 0000-0002-5836-4646
Philippe CeruseLaboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France.
Gersende AlphonseLaboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France.ORCID 0000-0001-5529-2555
Anne-Sophie WoznyLaboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France.ORCID 0000-0003-0247-2653
Claire Rodriguez-LafrasseLaboratory of Cellular and Molecular Radiobiology, UMR CNRS5822/IP2I, Lyon-Sud Medical School, Univ Lyon 1, Lyon University, 69921 Oullins, France.
Université Claude Bernard Lyon 1 · FRChirurgie et extrémité céphalique, caractérisation morphologique et fonctionnelle · FR

Funding

Cancéropôle CLARA CHEMRADLABEX PRIMES ANR-11-LABX-0063Ligue Nationale Contre le Cancer Ligue de Haute-SavoieUniversity of Lyon System ANR-11-IDEX-0007
6 · The paper itself

Abstract

Squamous cell carcinoma is the most common type of head and neck cancer (HNSCC) with a disease-free survival at 3 years that does not exceed 30%. Biomarkers able to predict clinical outcomes are clearly needed. The purpose of this study was to investigate whether a short-term culture of tumour fragments irradiated ex vivo could anticipate patient responses to chemo- and/or radiotherapies. Biopsies were collected prior to treatment from a cohort of 28 patients with non-operable tumours of the oral cavity or oropharynx, and then cultured ex vivo. Short-term biopsy slice culture is a robust method that keeps cells viable for 7 days. Different biomarkers involved in the stemness status (CD44) or the DNA damage response (pATM and γ-H2AX) were investigated for their potential to predict the treatment response. A higher expression of all these markers was predictive of a poor response to treatment. This allowed the stratification of responder or non-responder patients to treatment. Moreover, the ratio for the expression of the three markers 24 h after 4 Gy irradiation versus 0 Gy was higher in responder than in non-responder patients. Finally, combining these biomarkers greatly improved their predictive potential, especially when the γ-H2AX ratio was associated with the CD44 ratio or the pATM ratio. These results encourage further evaluation of these biomarkers in a larger cohort of patients.

Indexed as

Biomarkers, TumorAtaxia Telangiectasia Mutated ProteinsBiopsyCarcinoma, Squamous CellDisease SusceptibilityDNA DamageFemaleGene ExpressionGene Expression Regulation, NeoplasticHistonesHumansHyaluronan ReceptorsImmunohistochemistryMaleMouth NeoplasmsPrognosisAtaxia Telangiectasia Mutated ProteinsATM protein, humanBiomarkers, TumorCD44 protein, humanHistonesHyaluronan ReceptorsCD44DNA damage responseex vivo cultureHNSCCpATMpredictive biomarkerγ-H2AX foci

Identifiers

PMID35055060
PMCPMC8775909
OpenAlexW4205111434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.